Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives
- How do you define ADR?
- How common are ADRs?
- What are the costs of ADRs?
- Benefit-to-risk profile
- Classification of ADRs (1)
- Classification of ADRs (2)
- Pharmacokinetics and pharmacodynamics
- PK-PD Paradigm
- Route of oral medication
- Pharmacology
- Example of a type A ADR (1)
- Schizophrenia
- Dopamine hypothesis
- Correllation between dose-effect
- CNS dopamine pathway
- Dopamine receptors neuroanatomical distributions
- Example of a type A ADR
- Example of a type B ADR
- Mechanism of drug induced toxicity
- Carbamazepine-induced erythema multiforme
- Variability in drug response
- Summary
- Goal of pharmacogenetics
- Pharmacogenetics
- Genotype, phenotype - definitions
- How genotype and phenotype related to each other
- Gene, polymorphism, allele - definitions
- PK-PD paradigm in pharmacogenetics
- Route of psychotrophic drugs
- Polygenic drug response
- Comic relief
- Demographic and environmental factors in ADRs
- Examples of G-E interactions
- Functional polymorphisms in CYP1A2
- PGX methods applied to ADRs
- Central hypotheses
- Genetic association strategy
- Alternative genetic association strategy
- Candidate gene polymorphisms
- Selected examples
- Example of PK polymorphism and ADR
- PGX as applied to debrisoquine
- PGX as applied to succinylcholine
- Example of PD polymorphism and ADR
- PGX as applied to beta-adrenergic agonists
- PGX as applied to quetiapine
- Long QT syndrome mechanism
- Limitations to current strategies
- What are endophenotypes?
- Genotype-endophenotype-phenotype
- Endophenotype of D1 receptor alleles
- Endophenotype of DRD1 Ddel polymorphism
- Other examples and references
- Phase 1 CYP450 polymorphisms and ADRs
- PD polymorphisms and ADRs
- Phase 2 enzyme polymorphisms and ADRs
- Target and transporter polymorphisms and ADRs
- HLA immunoregion polymorphism and ADR
- Possibilities for the furture
- Future directions
- More to come
Topics Covered
- Type A and B Adverse Drug Reactions (ADRs)
- Pharmacokineticpharmacodynamic paradigm
- ADME framework
- Mechanisms of ADRs
- Pharmacogenetics and pharmacogenomics
- Polygenic traits
- Environmental factors
- Phenotype and endophenotype
- Candidate genes
- Association and linkage disequilibrium
Links
Series:
Categories:
Talk Citation
Masellis, M. (2007, October 1). Of genes and drugs: genetic determinants of adverse drug reactions [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 25, 2024, from https://doi.org/10.69645/WPSE4402.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Mario Masellis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Of genes and drugs: genetic determinants of adverse drug reactions
Published on October 1, 2007
41 min